Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Department of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg.
Adv Cancer Res. 2020;145:99-138. doi: 10.1016/bs.acr.2019.12.001. Epub 2020 Feb 14.
Chemokines regulate directed cell migration, proliferation and survival and are key components in cancer biology. They exert their functions by interacting with seven-transmembrane domain receptors that signal through G proteins (GPCRs). A subgroup of four chemokine receptors known as the atypical chemokine receptors (ACKRs) has emerged as essential regulators of the chemokine functions. ACKRs play diverse and complex roles in tumor biology from tumor initiation to metastasis, including cancer cell proliferation, adherence to endothelium, epithelial-mesenchymal transition (EMT), extravasation from blood vessels, tumor-associated angiogenesis or protection from immunological responses. This chapter gives an overview on the established and emerging roles that the atypical chemokine receptors ACKR1, ACKR2, ACKR3 and ACKR4 play in the different phases of cancer development and dissemination, their clinical relevance, as well as on the hurdles to overcome in ACKRs targeting as cancer therapy.
趋化因子调节定向细胞迁移、增殖和存活,是癌症生物学的关键组成部分。它们通过与通过 G 蛋白 (GPCR) 信号转导的七跨膜域受体相互作用发挥功能。一组称为非典型趋化因子受体 (ACKR) 的四个趋化因子受体亚组已成为趋化因子功能的重要调节剂。ACKR 在肿瘤生物学中发挥着从肿瘤起始到转移的多样化和复杂作用,包括癌细胞增殖、与内皮细胞黏附、上皮-间充质转化 (EMT)、从血管外渗、肿瘤相关血管生成或免受免疫反应的保护。本章概述了非典型趋化因子受体 ACKR1、ACKR2、ACKR3 和 ACKR4 在癌症发展和传播的不同阶段所扮演的既定和新兴角色、它们的临床相关性,以及在将 ACKR 作为癌症治疗的靶点时需要克服的障碍。